{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o Tirzepatide?<\/h3>\n<p style=\"margin: 0;\"><strong>Tirzepatide<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active studies molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published studies, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, esqueleto baseado em GIP com Aib<sup>2<\/sup>, Aib<sup>13<\/sup>, e Lys<sup>20<\/sup>-C20 \u00e1cido di\u00e1cido graxo acila\u00e7\u00e3o via espa\u00e7ador \u03b3Glu-\u03b3Glu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Tirzepatide?<\/h2>\n<p><strong>Tirzepatide<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide&#8217;s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile. Tirzepatide&#8217;s well-characterised structure has empirical formula C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published studies. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For broader incretin studies, see our <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> p\u00e1ginas de produtos. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Coagonismo Dual dos Receptores GLP-1 \/ GIP<\/h2>\n<p>O que diferencia o tirzepatide dos pept\u00eddeos de incretina \u00fanica anteriores \u00e9 a sua <strong>ativa\u00e7\u00e3o equilibrada de dois receptores distintos<\/strong>, each contributing complementary metabolic effects observed in published studies:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor GLP-1 \u2014 saciedade, secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2, esvaziamento g\u00e1strico<\/strong> \u2014 O tirzepatide liga-se ao receptor GLP-1 com afinidade compar\u00e1vel ao GLP-1 nativo, ativando a adenilil ciclase acoplada a G\u03b1<sub>s<\/sub>e a sinaliza\u00e7\u00e3o cAMP\/PKA a jusante. Isto produz os efeitos can\u00f3nicos do GLP-1: potencia\u00e7\u00e3o dependente da glicose da secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2 pancre\u00e1ticas, supress\u00e3o do glucagon das c\u00e9lulas \u03b1, atraso no esvaziamento g\u00e1strico e efeitos de supress\u00e3o do apetite central via neur\u00f3nios POMC do n\u00facleo arqueado. Este mecanismo sobrep\u00f5e-se ao do semaglutide.<\/li>\n<li><strong>Ativa\u00e7\u00e3o do receptor GIP \u2014 lip\u00f3lise dos adip\u00f3citos, gasto energ\u00e9tico, suporte das c\u00e9lulas \u03b2<\/strong> \u2014 The GIP component is what makes tirzepatide pharmacologically distinct. GIP receptor activation enhances insulin secretion in a glucose-dependent manner (complementary to GLP-1&#8217;s effect), but also acts on adipocytes to promote lipolysis under fasting conditions while supporting triglyceride storage in the fed state. Studies suggests GIP-receptor signaling also raises resting energy expenditure modestly and acts in CNS regions distinct from GLP-1, including the dorsomedial hypothalamus. The net effect is an additive body-weight signal beyond what GLP-1 alone produces.<\/li>\n<li><strong>Equil\u00edbrio dos receptores e ajuste estrutural<\/strong> \u2014 In radioligand-binding assays, tirzepatide shows higher affinity for the GIP receptor than for the GLP-1 receptor \u2014 an unusual ratio that distinguishes it from earlier dual-agonist candidates. The asymmetry is intentional: the GIP backbone allows higher GIP-receptor potency while the engineered modifications preserve sufficient GLP-1 activity. Tirzepatide is sometimes described as &#8220;GIP-biased&#8221; in receptor pharmacology, which has implications for the differential signalling observed in study models.<\/li>\n<\/ul>\n<p>The C20 fatty diacid acyl tether at lysine 20 binds reversibly to circulating serum albumin, forming a peptide depot that protects tirzepatide from renal clearance and produces the ~120-hour plasma half-life. The double Aib substitution (positions 2 and 13) prevents DPP-4 cleavage at two distinct sites, providing redundant proteolytic protection. Together these structural features convert what would otherwise be a short-acting incretin into a once-weekly peptide. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Tirzepatide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Controlo glic\u00e9mico e sensibilidade \u00e0 insulina<\/strong> \u2014 compara\u00e7\u00e3o direta com semaglutida e outros monoagonistas GLP-1 (Frias et al., NEJM 2021 SURPASS-2); modelos de roedores db\/db, ZDF e dieta rica em gordura; efeitos em substitutos de HbA1c, glicemia em jejum e par\u00e2metros de clamp hiperinsulin\u00e9mico-euglic\u00e9mico<\/li>\n<li><strong>Body weight and adiposity studies<\/strong> \u2014 the SURMOUNT-1 trial showed ~22% body weight reduction at 15\u00a0mg weekly over 72 weeks, the largest single-peptide effect documented in clinical studies at the time; rodent DIO models, body composition (DEXA \/ MRI), respiratory exchange ratio<\/li>\n<li><strong>MASLD\/MASH (doen\u00e7a hep\u00e1tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> \u2014 conte\u00fado de triglic\u00e9ridos hep\u00e1ticos, ALT\/AST, estadiamento de fibrose; conjunto de dados do ensaio SYNERGY-NASH<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efeitos na press\u00e3o arterial, perfis lip\u00eddicos, progress\u00e3o da aterosclerose em ApoE<sup>-\/-<\/sup> Investiga\u00e7\u00e3o sobre apneia do sono<\/li>\n<li><strong>Sleep apnoea studies<\/strong> Prote\u00e7\u00e3o renal em modelos de nefropatia diab\u00e9tica<\/li>\n<li><strong>Prote\u00e7\u00e3o renal em modelos de nefropatia diab\u00e9tica<\/strong> \u2014 albumin\u00faria, taxa de filtra\u00e7\u00e3o glomerular, expans\u00e3o mesangial em nefropatia diab\u00e9tica induzida por estreptozotocina e em ratinhos Akita<\/li>\n<li><strong>Comparative incretin peptide studies<\/strong> \u2014 refer\u00eancia para compara\u00e7\u00f5es de agonista duplo vs agonista \u00fanico vs agonista triplo. Consulte o nosso <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\">Guia Retatrutide vs Tirzepatide<\/a> e ao <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> p\u00e1gina do produto para comparadores irm\u00e3os.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o tirzepatide se enquadra no cen\u00e1rio dos pept\u00eddeos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (agonista triplo GLP-1\/GIP\/glucagon, o comparador de pr\u00f3xima gera\u00e7\u00e3o) e <a href=\"https:\/\/medsbase.com\/pt-pt\/ozempic-vs-mounjaro\/\">o nosso guia Ozempic vs Mounjaro<\/a>. Explore a <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Tirzepatide in eleven lyophilized vial strengths covering the full dose-titration range from pilot dosing through multi-month bulk protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosagem piloto, titula\u00e7\u00e3o de n\u00edvel baixo, ciclos curtos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maintenance strength, mid-titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">For\u00e7a-alvo cl\u00ednica equivalente (dose m\u00e1xima aprovada para humanos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose arm, exploratory protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de v\u00e1rias semanas a partir de um \u00fanico frasco, menor volume de reconstitui\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lower per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-month protocols, comparative dose-response studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose comparative arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, low per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudos multicohorte, protocolos de v\u00e1rios meses<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum Bulk packs vial, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All eleven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful for users minimising injection volume or running extended multi-month protocols from a single vial. Because reconstituted solution is stable for ~30 days, the optimal vial size for a given protocol depends on weekly dose \u00d7 weeks-per-vial trade-off. <\/p>\n<h2>Como Comparar \u2014 Tirzepatide vs Semaglutide vs Retatrutide<\/h2>\n<p>Tirzepatide sits at the centre of the modern incretin-agonist studies landscape, between the single-receptor <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> (apenas GLP-1) e o recetor triplo <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (GLP-1 + GIP + glucagon). Each step up the receptor ladder produces a progressively larger body-weight effect in head-to-head studies but also broader systemic signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (\u00fanico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (duplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucagon (triplo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estrutura base do p\u00e9ptido<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semelhante ao GIP (39 aa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~120 horas (~5 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Liga\u00e7\u00e3o de \u00e1cido gordo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 di\u00e1cido + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Refer\u00eancia da marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Investigacional (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.25\u20132.4 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2.5\u201315 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal nos ensaios<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22% (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Controlo glic\u00e9mico, cardiovascular<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Combina\u00e7\u00e3o de controlo glic\u00e9mico + peso corporal, MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maior efeito no peso corporal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The head-to-head SURPASS-2 trial (Frias et al., NEJM 2021) showed superior HbA1c and body-weight reduction with tirzepatide 15\u00a0mg vs semaglutide 1\u00a0mg over 40 weeks \u2014 one of the largest direct comparison datasets in incretin studies. For methodological detail on the dual- vs triple-agonist landscape, read <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida: agonista triplo vs duplo<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide), magnitude of effect (greater with tirzepatide and retatrutide), and the strength of available trial data (extensive for semaglutide and tirzepatide, still maturing for retatrutide). <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo sem abertura, congele a \u221220 \u00b0C. A tirzepatida liofilizada \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o at\u00e9 24 meses e a \u221220 \u00b0C at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injecte \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco do p\u00e9ptido (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 10 mg, 2,0 mL de \u00e1gua bacteriost\u00e1tica produzem uma concentra\u00e7\u00e3o de trabalho de 5 mg\/mL \u2014 10 marcas numa seringa de insulina U-100 equivalem a 500 mcg. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> agite vigorosamente \u2014 e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser l\u00edmpida e incolor. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because tirzepatide is dosed once weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20134 weeks of dosing depending on target dose; a 50\u00a0mg vial supports 10\u201320 weeks at clinical-equivalent doses. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Tirzepatide used for in studies?<\/h3>\n<p>Tirzepatide is used in studies investigating glycaemic control, insulin sensitivity, body weight and adiposity, MASLD\/MASH liver disease, cardiovascular endpoints, sleep apnoea, and diabetic nephropathy. It is the most extensively characterised dual GLP-1\/GIP agonist and is the standard comparator arm for newer multi-agonist peptide studies. The pharmaceutical-grade tirzepatide sold here is <strong>n\u00e3o<\/strong> FDA-approved for human therapeutic use and is supplied strictly for clinical studies. <\/p>\n<h3>Como \u00e9 que o Tirzepatide difere do Semaglutide?<\/h3>\n<p>A diferen\u00e7a estrutural est\u00e1 no perfil de recetores e na estrutura pept\u00eddica. O Tirzepatide \u00e9 constru\u00eddo sobre a estrutura de 39 amino\u00e1cidos do GIP e co-ativa tanto os recetores GIP como GLP-1. O Semaglutide \u00e9 constru\u00eddo sobre a estrutura de 31 amino\u00e1cidos do GLP-1 e ativa apenas o recetor GLP-1. O componente GIP no Tirzepatide adiciona lip\u00f3lise no tecido adiposo e aumentos modestos no gasto energ\u00e9tico que os p\u00e9ptidos apenas GLP-1 n\u00e3o produzem. Em ensaios comparativos diretos (SURPASS-2), o Tirzepatide 15 mg produziu redu\u00e7\u00e3o superior de HbA1c e peso corporal em compara\u00e7\u00e3o com o Semaglutide 1 mg ao longo de 40 semanas. <\/p>\n<h3>Como \u00e9 que o Tirzepatide difere do Retatrutide?<\/h3>\n<p>Ambos s\u00e3o baseados em estruturas GIP, mas o Retatrutide adiciona atividade do recetor de glucagon al\u00e9m do GLP-1 e GIP \u2014 tornando-o um triplo agonista. O componente adicional de glucagon contribui ainda mais para o gasto energ\u00e9tico e a lip\u00f3lise dos adip\u00f3citos. Os dados publicados da Fase 2 do Retatrutide mostram uma redu\u00e7\u00e3o de peso corporal de ~24% com 12 mg semanais, excedendo modestamente os 22% do Tirzepatide no SURMOUNT-1. O Tirzepatide tem o conjunto de dados de ensaios mais maduro; o Retatrutide ainda est\u00e1 em desenvolvimento em fase avan\u00e7ada. <\/p>\n<h3>What is the typical Tirzepatide dose?<\/h3>\n<p>Os protocolos publicados utilizam tipicamente um esquema de titula\u00e7\u00e3o come\u00e7ando com 2,5 mg semanais e aumentando 2,5 mg a cada 4 semanas at\u00e9 uma dose de manuten\u00e7\u00e3o de 5\u201315 mg semanais. Um frasco de 10 mg reconstitu\u00eddo com 2,0 mL de \u00e1gua bacteriost\u00e1tica produz 5 mg\/mL \u2014 10 marcas numa seringa U-100 equivalem a 500 mcg. <\/p>\n<h3>O Tirzepatide \u00e9 aprovado pela FDA?<\/h3>\n<p>Pharmaceutical tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023), manufactured to GMP standards by Eli Lilly. <\/p>\n<h3>Como deve ser armazenado o Tirzepatide?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabalho a curto prazo, ou \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar no prazo de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam o p\u00e9ptido. Proteger da luz direta em todos os momentos. <\/p>\n<h3>Como reconstituir o Tirzepatide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 2 a 5 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 l\u00edmpida e incolor. Para um frasco de 10 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 5 mg\/mL. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries Tirzepatide in eleven lyophilized vial strengths: 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg, 80\u00a0mg, 100\u00a0mg, and 120\u00a0mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Qual \u00e9 a meia-vida do Tirzepatide?<\/h3>\n<p>O Tirzepatide tem uma meia-vida plasm\u00e1tica de aproximadamente 120 horas (~5 dias) ap\u00f3s administra\u00e7\u00e3o subcut\u00e2nea. A meia-vida \u00e9 alcan\u00e7ada atrav\u00e9s da liga\u00e7\u00e3o reversa \u00e0 albumina s\u00e9rica circulante via o \u00e1cido di\u00e1cido gordo C20 na lisina 20, que protege o p\u00e9ptido da depura\u00e7\u00e3o renal. Combinado com a dupla substitui\u00e7\u00e3o de Aib (posi\u00e7\u00f5es 2 e 13) que bloqueia a clivagem pela DPP-4, isto confere ao tirzepatide um regime posol\u00f3gico semanal, compar\u00e1vel \u00e0 meia-vida de ~165 horas do semaglutida. <\/p>\n<h3>Porque \u00e9 que o Tirzepatide produz maior perda de peso do que o Semaglutida?<\/h3>\n<p>The most-cited mechanism is the GIP-receptor component. GIP-receptor activation contributes additional effects that GLP-1 alone doesn&#8217;t produce: enhanced adipocyte lipolysis under fasting conditions, modest increases in resting energy expenditure, and CNS effects in the dorsomedial hypothalamus distinct from arcuate-nucleus GLP-1 signalling. The combined dual signal produces an additive body-weight reduction beyond GLP-1 alone in head-to-head study models. <\/p>\n<h3>Does Tirzepatide cause side reported effects?<\/h3>\n<p>O achado mais consistente \u00e9 gastrointestinal \u2014 n\u00e1useas, supress\u00e3o transit\u00f3ria do apetite e esvaziamento g\u00e1strico retardado s\u00e3o dose-dependentes e tendem a atenuar-se ao longo de 4 a 8 semanas de dosagem cont\u00ednua \u00e0 medida que se desenvolve taquifilaxia do recetor. Achados menos comuns incluem efeitos na motilidade da ves\u00edcula biliar e (em modelos de roedores com sensibilidade das c\u00e9lulas C da tiroide) hiperplasia das c\u00e9lulas C \u2014 o \u00faltimo \u00e9 um sinal espec\u00edfico da esp\u00e9cie que n\u00e3o se traduziu em humanos em acompanhamento cl\u00ednico a longo prazo. <\/p>\n<h3>Can Tirzepatide and Semaglutide be compared in studies?<\/h3>\n<p>Sim \u2014 a compara\u00e7\u00e3o direta \u00e9 uma das quest\u00f5es mais ativamente estudadas na farmacologia das incretinas. O ensaio cl\u00ednico SURPASS-2 comparou diretamente tirzepatida 15 mg com semaglutida 1 mg em pacientes com diabetes tipo 2; evid\u00eancias pr\u00e9-cl\u00ednicas e crescentes evid\u00eancias do mundo real continuam a estender a compara\u00e7\u00e3o para peso corporal, MASH e endpoints cardiovasculares. A semaglutida permanece o comparador padr\u00e3o GLP-1; a tirzepatida \u00e9 o comparador padr\u00e3o de agonista duplo. <\/p>\n<h3>How long does Tirzepatide take to show effects in preclinical studies?<\/h3>\n<p>Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1\u20132 weeks of weekly dosing and continue to accrue through 8\u201316 weeks. Maximum effect on body composition is typically observed after 16\u201324 weeks of continuous dosing in study models, mirroring the human-trial trajectory. <\/p>\n<h3>Posso encomendar Tirzepatida para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Tirzepatida para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos independente. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Single GLP-1 agonist (Ozempic\/Wegovy\/Rybelsus active) \u2014 standard glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/pt-pt\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 next-generation multi-axis metabolic support<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<li><a href=\"\/pt-pt\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded exercise-mimetic peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog for growth-axis studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Compare o panorama das incretinas de a\u00e7\u00e3o prolongada<\/strong><\/p>\n<p style=\"margin: 0;\">Leia os nossos guias de compara\u00e7\u00e3o direta: <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\"><strong>Retatrutida vs Tirzepatida \u2014 agonista triplo vs agonista duplo<\/strong><\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. Aborda a farmacologia dos recetores, engenharia de sequ\u00eancias, meia-vida, rela\u00e7\u00e3o dose-resposta e os dados de ensaios comparativos que distinguem o tirzepatide do semaglutide (SURPASS-2) e dos resultados da Fase 2 do retatrutide como triplo agonista.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Agonista duplo dos recetores GLP-1 + GIP<br \/>\n\u2705 Maior efeito de peso corporal com um \u00fanico p\u00e9ptido<br \/>\n\u2705 Supports glycaemic control<br \/>\n\u2705 Lip\u00f3lise dos adip\u00f3citos e gasto energ\u00e9tico<br \/>\n\u2705 Protocolos de doseamento semanal<\/p>\n<p><strong>Tirzepatide<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":["post-70674","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-tirzepatide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}